Innograce Medical's Integrated Ultrasonic-High-Frequency Surgical Device with 7mm Vessel-Sealing Capability Receives China NMPA Approval, Reshaping Provincial Consortium Procurement Landscape

Recently, the ultrasonic high-frequency surgical integrated operating device independently developed by Innolcon Medical Technology (Suzhou) Co., Ltd. has been officially approved for a Class III medical device registration certificate by the National Medical Products Administration. This product features both high-frequency and ultrasonic energy modes. In ultrasonic energy mode, the disposable ultrasonic soft tissue surgical blade can seal blood vessels with a diameter of up to 7mm. This is another significant product launch by Innolcon Medical following the acquisition of the first domestically produced ultrasonic scalpel capable of sealing 5mm vessels in August 2020, marking a new phase where China-produced ultrasonic scalpels are advancing towards the high-end market.

Ultrasonic High-Frequency Surgical Integrated Operating Equipment

In the registration review of ultrasonic scalpel products and the provincial alliance procurement in China, the ultrasonic scalpel tips are generally divided into three quality levels based on their ability to seal blood vessels: 3mm, 5mm, and 7mm. The larger the diameter of the blood vessel that can be sealed, the higher the performance indicators of the product, such as cutting speed and hemostatic capability.

In the high-end field of 7mm quality level, it has long been monopolized by imported brands with high prices that patients can hardly afford. The significant approval of this product not only demonstrates the technical strength of Innolcon Medical as a unicorn enterprise in the domestic ultrasonic knife niche, as well as the progress of China's medical device manufacturing industry, but also highlights the remarkable enhancement of China's independent innovation capability in medical technology. It will also have a significant impact on the procurement patterns of provincial alliances and the future national procurement landscape in China.

In clinical trials comparing with imported products, this product not only achieved a 98.1% success rate in vascular cutting and sealing but also matched imported products in core clinical indicators such as intraoperative blood loss, postoperative drainage volume, cutting speed, and hemostasis satisfaction, earning high praise from clinicians.

Disposable Ultrasonic Soft Tissue Surgical Blade

Disposable Integrated Ultrasonic Soft Tissue Surgical Blade

At the end of 2021, in the volume-based procurement of ultrasonic scalpel heads led by Guangdong and involving a 16-province alliance, the listing of domestically produced 5mm ultrasonic scalpels represented by Innolcon Medical unveiled the curtain for significant price reductions of ultrasonic scalpels. In this volume-based procurement, the average price reduction for ultrasonic scalpel heads was 70.11%.

Due to the significantly simplified procurement process, reduced intermediate steps, and improved procurement efficiency brought by the provincial alliance's bulk purchasing, domestic brands have rapidly risen. Large-scale procurement has also promoted the integration and rapid development of upstream and downstream industrial chains. The production cost of domestically-made ultrasonic scalpels has further decreased, while quality levels have steadily improved. Bulk purchasing with guaranteed volume has allowed a large number of patients to access affordable and high-quality products. It has also driven the survival of the fittest and transformation within the medical device industry, helping to build a fairer, more competitive, and orderly market environment.

Innolcon Medical, with its core technology in the high-end ultrasonic surgery field and relentless investment in R&D, has established four major product lines: surgery, ophthalmology, orthopedics, and ultrasonic aesthetics. It is committed to becoming a leading enterprise in high-end surgical medical devices both in China and internationally.

Innolcon Medical's products continue to achieve new breakthroughs in overseas expansion.As of November 2024, Innolcon Medical's ultrasonic scalpel (with 7mm blade), ultrasonic high-frequency integrated device, electrosurgical energy platform, and phacoemulsification products have been progressively advanced and approved in markets such as the EU, South Korea, and Brazil.

This series of certifications marks Innolcon Medical's further expansion into the international market, and in the future, it will provide advanced surgical solutions to more medical institutions.

Innolcon Medical will adhere to innovation, continuously surpassing itself, and practice the development concept of "Innovative Technology, Globally Shared," striving to make its products available in every corner of the world where they are needed.

Disclaimer: This article is intended solely for professional partners in the pharmaceutical, medical, and other health industries. It is for use by medical and pharmaceutical professionals only and is not targeted at the general consumer public.